Santhera Pharmaceuticals Halbjahresergebnisse für die sechs Monate bis zum 30. Juni 2026

Santhera reported H1 2026 revenue of CHF 48.3 million, up 101% year over year, driven by 48% product-sales growth to CHF 17.2 million and CHF 29.1 million of licensing and milestone revenue, principally from the Nxera APAC agreement. The operating loss narrowed to CHF 6.6 million from CHF 35.4 million, while cash rose to CHF 41.8 million from CHF 22.4 million at year-end 2025; however, the company still posted a CHF 21.5 million net loss amid CHF 21.2 million of finance costs. Santhera maintained its FY2026 revenue guidance of CHF 80-90 million and reiterated medium-term revenue targets of about CHF 140 million excluding milestones in 2028 and CHF 250 million in 2030, supported by AGAMREE commercialization across four of the five largest EU markets and expanded APAC access.

Analysis

The key valuation question is not the reported revenue beat but the durability of gross profit after contractual pass-throughs. SANN’s first-half earnings were materially flattered by non-recurring licensing cash, while milestone obligations and royalties absorb a meaningful share of commercial scale; the market should value the company on recurring direct-market product sales plus normalized partner royalties, not headline revenue. The immediate positive is that a broader reimbursement footprint should improve prescription persistence and reduce launch friction, but the earnings conversion will lag revenue as new-country launches carry working-capital and field-force costs.

The more consequential 2027 risk is a simultaneous cash-flow squeeze: inventory purchases are pulled forward while German pricing resets lower, and US royalty economics step down as the partner’s sales cross contractual thresholds. This creates a potential 1H27 funding scare even if the long-run demand thesis remains intact, particularly given negative equity and material financial expenses. Management’s assertion that no financing is required is not independently sufficient; the falsification point is year-end cash, net working-capital build, and whether Germany volume growth offsets the mandated net-price reduction.

SANN’s underappreciated upside is strategic rather than near-term P&L: as AGAMREE becomes embedded in DMD treatment pathways, the asset’s value to larger rare-disease platforms rises, especially if pediatric-label expansion and APAC approvals convert into de-risked royalty streams. Conversely, the adult real-world evidence is hypothesis-generating rather than label-expanding evidence and should not yet be capitalized as a new indication. CPRX is no longer a clean public read-through following its acquisition; SANN remains the direct listed exposure, but position sizing must account for SIX liquidity and financing-sensitive volatility.

Key Decisions for Investors

• Initiate only a small tactical long in SANN after the investor call if management provides recurring 2026 product-revenue guidance, Germany 2027 net-price sensitivity, and a quarterly cash bridge; target a 1-3 month rerating on cleaner recurring-revenue disclosure, with a hard exit on any indication of a 2027 equity raise.
• Do not underwrite SANN on reported 2026 revenue or the APAC deal’s headline value. Model the business on recurring product sales and royalty receipts, haircut contingent milestones to zero, and require evidence that 2H26 product growth—not China shipment timing or one-time license income—carries full-year guidance.
• Set a 1H27 risk alert for cash falling materially below management’s implied year-end level, German unit growth failing to outpace the price reset, or partner royalty growth lagging end-market sales. Any of these would likely drive multiple compression and reopen dilution risk.
• Avoid using CPRX as a pair or sympathy trade: it has been acquired and no longer offers a liquid, independent public-market expression of AGAMREE’s US uptake. For SANN, avoid options unless open interest and spreads are independently confirmed.